Loading
A phase 2 trial of Fludarabine, Cyclophosphamide in non-hodgkin lymphoma, run by Celgene, active and no longer recruiting.
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) is a phase 2 interventional study registered as NCT04245839 by Celgene, with 276 participants planned, started 2020-07-14 and due to reach its primary completion in 2031-09-30. Interventions recorded: Fludarabine, Cyclophosphamide, JCAR017. Conditions listed: Lymphoma, Non-Hodgkin. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/